-
ArticlePublication 2008Potential Cost-Effectiveness of Vaccination against Herpes Zoster and Post-Herpetic Neuralgia
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine …
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine against herpes zoster (HZ) and post-herpetic neuralgia (PHN). The authors used a cohort model to estimate the burden of HZ and the cost-effectiveness of HZ vaccination from a ministry of health perspective using Canadian population-based data. They examined different ages at vaccination and conducted probabilistic sensitivity analysis.There are about 130,000 new cases of HZ, 17,000 cases of PHN and 20 deaths…
Dynamic Transmission | Preferences/Values | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | North America -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Mathematical Models | Health Outcomes | Evidence Synthesis | Decision Analysis | Health Systems | Policy/Regulation | Health/Medicine | North America -
ArticlePublication 2015Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) …
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) that at the time of this study was approved for persons age 50+. The authors used a Markov model to simulate adults aged 50 years over a lifetime from a societal perspective; outcomes included the number of HZ and postherpetic neuralgia (PHN) cases prevented and the incremental cost per quality-adjusted life-year (QALY) saved. Their focus was on the cost effectiveness…
State-Transition | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | North America -
ArticlePublication 2013Vaccination against Herpes Zoster and Postherpetic Neuralgia in France: A Cost-Effectiveness Analysis
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for …
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for the 65 year + population in France. The authors compared vaccinating all adults over 65 years versus adults from 70-79 years, over their lifetimes, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol 5D) utilities from the literature. Results showed incremental cost-effective ratios d between €9513 and €12,304 per quality-adjusted life…
State-Transition | Preferences/Values | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Europe -
ArticlePublication 2015Distribution of Health Effects and Cost-Effectiveness of Varicella Vaccination
This article reports on an analysis of the impact of universal childhood varicella vaccination on the …
This article reports on an analysis of the impact of universal childhood varicella vaccination on the incidence of herpes zoster (HZ) using dynamic transmission modelling and cost-effectiveness analyses. Scenarios that are considered differ by whether or not immune boosting is included, and whether or not reactivation of vaccine virus is possible. The authors report that health effects of varicella vaccination in scenarios with immune boosting are unevenly distributed: cohorts born just before introduction of vaccination and…
Dynamic Transmission | Preferences/Values | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | Europe -
Working PaperPublication 2017Cost-Effectiveness Analysis of Adjuvanted Subunit Vaccine for Prevention of Herpes Zoster
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 …
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 years of age, accounting for more than 1 million cases of HZ annually in the United States. A live attenuated vaccine (LAV) for HZ is U.S. FDA approved for persons 50 years or older, though CDC Advisory Committee on Immunization Practices (ACIP) recommendations are only for persons beginning at age 60 years. LAV efficacy at preventing HZ is ~70% for…
Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | North America
6 Shown
Teaching Resources
Collections
Format
Learner Level
Teaching Topic